Mr. John Claude, in conjunction with Dr. Yakov Katsnelson, designed and developed the original tACS waveform that is marketed as Nexalin Technology. Mr. Claude now leads all engineering, research, and development at Nexalin Technology. Additionally, Mr. Claude has an extensive background in regulatory, compliance and quality management. Mr. Claude graduated from the University of Notre Dame with a BS in Physiology. He subsequently received an ME in Biomedical Engineering from the University of Virginia. Mr. Claude has designed and built advanced technologies for NASA, NIH, Stanford Medical Center, and the Palo Alto Veterans Administration.